fda compounding glp-1 enforcement news today 2025 4-3-2026 💔❤️‍🩹👹, xoxo reta rat, #wellness #glp1 #medicine #health #news Guest Letter: Concerns About Compounded

You are not overreacting, and you are not failing because meals need to be smaller, simpler, and more intentional right now

Notable Investors: Pre-acquisition, key investors and shareholders included Novo Holdings, Elliot Investment Management, and The Blackstone Group

When studying the mechanism of berberine in the treatment of diabetes, a study has already pointed out that berberine can promote insulin secretion, improve insulin resistance and inhibit pancreatic islet cell dysfunction (Sun S

Burak Altintas, MD, an orthopedist with UTMB, who was not involved in this study, further highlighted the following limitations of the research: The limitations include retrospective design and likely residual confounding despite matching as fracture risk is influenced by many variables that are not reported [] Further, the comparison group is heterogeneous, combining another GLP-1 receptor agonist (dulaglutide) with two mechanistically different weight-loss medications

There is no competition for receptors, no metabolic overlap that would reduce effectiveness, and no known pharmacological interactions between the compounds